Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting

BACKGROUND: Rituximab has broad and increasing application in rheumatic diseases. It is known from lymphoma studies that natural killer (NK) cells can lyse rituximab-coated transformed B cells. However, the role of NK cells in mediating rituximab-induced depletion of non-malignant B cells is unknown...

Descripción completa

Detalles Bibliográficos
Autores principales: Merkt, Wolfgang, Lorenz, Hanns-Martin, Watzl, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024429/
https://www.ncbi.nlm.nih.gov/pubmed/27629249
http://dx.doi.org/10.1186/s13075-016-1101-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024429/
https://www.ncbi.nlm.nih.gov/pubmed/27629249
http://dx.doi.org/10.1186/s13075-016-1101-3

Ejemplares similares